文献速递哮喘

生物标志物指导管理减少非嗜酸性哮喘孕妇急性发作:一项随机对照试验的二次分析

Biomarker-guided management reduces exacerbations in non-eosinophilic asthma in pregnancy: A secondary analysis of a randomized controlled trial.
PubMed 文献 · Respirology · 2019-10-26

该随机对照试验二次分析比较症状控制算法与呼出气一氧化氮(FENO)指导算法在妊娠期哮喘中的治疗决策差异及对非嗜酸性哮喘(NEA)的疗效。220名非吸烟孕妇随机分组,FENO组NEA患者妊娠期急性发作率显著低于对照组(18.9% vs 44%,P=0.006),且中位每日吸入激素剂量更低。

要点

  • FENO指导算法使NEA孕妇急性发作率从44%降至18.9%(P=0.006)。
  • FENO组治疗更贴合表型:嗜酸性哮喘增加ICS,NEA增加ICS/LABA。
  • 间隔一个月的两次FENO算法应用即可产生减少急性发作的获益。

核心结论

  • FENO指导算法较症状控制算法更有效治疗妊娠期非嗜酸性哮喘,减少急性发作。
  • 获益并非因ICS过度治疗,反而发生在更低的中位每日ICS剂量下。

研究设计与样本

  • 双盲平行组随机对照试验的二次分析,妊娠22周前随机分组。
  • 共220名非吸烟哮喘孕妇(对照组109例,FENO组111例),共做出1006次治疗决策。

主要发现

  • 53%的孕妇为非嗜酸性哮喘(NEA),定义为基线血嗜酸性粒细胞<0.26×10^9/L且FENO≤29 ppb。
  • FENO组嗜酸性哮喘(EA)的ICS使用率从48%增至86%,NEA的ICS/LABA使用率从11%增至30%。
  • 仅NEA孕妇中,FENO组妊娠期急性发作率显著低于对照组(18.9% vs 44%,P=0.006)。

关键数值与推荐

  • NEA分类标准:基线血嗜酸性粒细胞<0.26×10^9/L且FENO≤29 ppb。
  • FENO指导算法:根据FENO调整ICS剂量,症状未控制时加用LABA。
  • 症状控制算法作为对照。

临床怎么用

  • 对妊娠期非嗜酸性哮喘孕妇,可采用FENO指导的ICS调整策略以减少急性发作。
  • 间隔一个月应用两次FENO算法即可产生获益,无需频繁调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The aim of this secondary analysis of a randomized controlled trial (RCT) of asthma management in pregnancy was to determine the treatment decision differences between a symptom control algorithm and a fractional exhaled nitric oxide (FENO)-guided algorithm, and whether the approach was effective in non-eosinophilic asthma (NEA). METHODS: In this double-blind parallel group RCT, women with asthma were randomized prior to 22 weeks gestation to treatment adjustment according to a symptom control algorithm (control group), or a FENO-guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long-acting beta-agonist (LABA) added for uncontrolled symptoms). NEA was classified as baseline blood eosinophils <0.26 × 109 /L and FENO ≤29 ppb. Exacerbations requiring medical intervention were recorded. RESULTS: Among 220 non-smokers (n = 109 control, n = 111 FENO), 1006 treatment decisions were made, with significant group differences after the first and second algorithm applications. 53% of women had NEA. Treatment was better targeted to phenotype in the FENO group: ICS use increased in eosinophilic asthma (EA, 48-86%), while ICS/LABA increased in NEA (11-30%). Fewer women in the FENO group had exacerbations during pregnancy in NEA only (18.9% FENO vs 44% control, P = 0.006). CONCLUSION: The FENO algorithm was more effective in treating NEA, resulting in reduced exacerbations, compared to a symptom control algorithm. This was not the result of ICS overtreatment, since the benefits occurred at a lower median daily ICS dose. Two applications of the FENO-guided algorithm, one month apart, were sufficient to achieve beneficial effects in terms of asthma exacerbations, among pregnant women with asthma.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Murphy VE, Porsbjerg CM, Robijn AL, et al. Biomarker-guided management reduces exacerbations in non-eosinophilic asthma in pregnancy: A secondary analysis of a randomized controlled trial. Respirology. 2019. PMID: 31656059. doi:10.1111/resp.13713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。